Eva Temkin discusses the broader implications of the Fifth Circuit Court of Appeals ruling to reverse FDA's flexible prescribing conditions for the abortion pill mifepristone and explains why the ruling could create an unprecedented ability for judges without scientific expertise to overturn FDA approval decisions